A p53-dependent biological response for miR-145 in both breast and colorectal cancer cells was described, suggesting that miR-145 re-expression therapy could be mainly envisioned in patients carrying TP53 wild-type tumors [58]. The gene discussed is TP53; the disease is colorectal cancer.